Washington, DC - Yesterday, the U.S. Food and Drug Administration released a final guidance, “Postmarketing Safety Reporting for Combination Products,” for applicants of combination products—products composed of two or more different types of medical products (i.e., drug, device or biologic)—to further clarify how they can comply with the 2016 final rule on postmarketing safety reporting requirements (PMSR) for combination products.

Although the PMSR regulations for drugs, devices and biological products have many similarities, each set of regulations establishes distinct safety reporting requirements, including standards and timeframes. This final guidance explains, among other things, which combination products are impacted by the PMSR requirements, how to submit reports, recordkeeping requirements, and how to avoid duplications when submitting safety information to the agency. This final guidance provides examples for both drug and device-led combination products with detailed flowcharts explaining which reports are required under the PMSR rule, and discusses the content for these reports, and when they are due to the FDA.

To ensure applicants have sufficient time to make necessary adjustments, the FDA announced in April that the agency does not intend to enforce the additional constituent part-based PMSR requirements until July 2020 for most combination products, and until January 2021 for vaccine combination product.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.